Sanofi acquires Dynavax for $2.2B, boosting its vaccine portfolio with HEPLISAV-B and a shingles candidate. Click for my ...
The deal adds hepatitis B and early-stage shingles vaccines as Sanofi faces pipeline pressure from tolebrutinib setback.
Sanofi (NASDAQ:SNY) is included among the 15 Global Dividend Stocks to Diversify Your Portfolio. Sanofi (NASDAQ:SNY) said on ...
The Manila Times on MSN
Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal
SANOFI said on Wednesday it will buy US biotech Dynavax Technologies for around $2.2 billion (1.9 billion euros) in an agreed deal that will add an adult hepatitis B vaccine and a promising ...
Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...
Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...
Johnson & Johnson has discontinued a mid-stage trial of its experimental drug for moderate to severe atopic dermatitis after ...
In March 2025, Japan’s Ministry of Health, Labour and Welfare has approved the marketing and manufacturing of Dupixent ...
The Chosun Ilbo on MSN
Global bio-pharmaceutical market to hit 1,400 trillion won by 2028
The global bio-pharmaceutical market is projected to surge to approximately 1,400 trillion won in about two years. Bio-pharmaceuticals refer to medicines made from biological materials such as human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback